Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer

By          

Oncology Reports, Vol. 28, Iss. 2, 2012-01 ,pp. : 721-727

Spandidos Publications

Access to resources Recommend Favorite

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

By Rossi David  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 231-235

Springer Publishing Company

Access to resources Recommend Favorite

Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group Experience

By Hotta Katsuyuki   Ueoka Hiroshi   Kiura Katsuyuki   Tabata Masahiro   Ogino Atsuko   Umemura Shigeki   Harita Shingo   Gemba Kenichi   Yonei Toshiro   Bessho Akihiro   Maeda Tadashi   Tanimoto Mitsune  

Acta Oncologica, Vol. 44, Iss. 7, 2005-10 ,pp. : 717-722

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 5, 2014-06 ,pp. : 646-650

Bentham Science Publishers

Access to resources Recommend Favorite

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

By Sun Jong-Mu   Won Young-Woong   Kim Seung   Kim Jung   Choi Yoon-La   Lee Jeeyun   Park Yeon   Ahn Jin   Park Keunchil   Ahn Myung-Ju  

Journal of Cancer Research and Clinical Oncology, Vol. 137, Iss. 4, 2011-04 ,pp. : 687-694

Springer Publishing Company

Access to resources Recommend Favorite